A Phase 2 Adult and Adolescent Angelman Syndrome Clinical Trial: A Randomized, Double-Blind, Safety and Efficacy Study of Gaboxadol

Trial Profile

A Phase 2 Adult and Adolescent Angelman Syndrome Clinical Trial: A Randomized, Double-Blind, Safety and Efficacy Study of Gaboxadol

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2018

At a glance

  • Drugs Gaboxadol - Ovid Therapeuticsgaboxadol (Primary)
  • Indications Angelman syndrome
  • Focus Adverse reactions
  • Acronyms STARS
  • Sponsors Ovid Therapeutics
  • Most Recent Events

    • 29 Mar 2018 Status changed from recruiting to active, no longer recruiting, according to an Ovid Therapeutics media release.
    • 29 Mar 2018 According to an Ovid Therapeutics media release, topline data from this trial is expected in third quarter of 2018.
    • 29 Nov 2017 Planned End Date changed from 1 Nov 2017 to 1 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top